john Given

943 posts

john Given

john Given

@JohnGivenjohn

Inscrit le Temmuz 2017
175 Abonnements71 Abonnés
john Given retweeté
TheJournal.ie
TheJournal.ie@thejournal_ie·
The new machine, the first of its kind to be installed in Ireland, will dramatically reduce the time it takes to reach a diagnosis from days to a matter of hours, the NBCRI said. jrnl.ie/7005558
TheJournal.ie tweet media
English
2
7
40
12.6K
john Given retweeté
Peter Forsberg MD
Peter Forsberg MD@ForsbergMD·
Our data from @ColoradoBlood is out now. We developed an approach using dex for excessive lymphocyte expansion after Cilta-Cel. Instituted along with more stringent bridging we subsequently observed improvements in non-relapse mortality and reduced severe atypical neurotox events
Robert Z. Orlowski@Myeloma_Doc

#Myeloma Paper of the Day: Dexamethasone prophylaxis for high lymphocyte expansion (ALC >5000/μL, which predicted severe early neurologic events/high mortality) post-cilta-cel in myeloma demonstrates promise for risk mitigation, including better OS: pubmed.ncbi.nlm.nih.gov/41894686/. #mmsm

English
2
3
30
4.1K
john Given retweeté
Thor Halfdanarson
Thor Halfdanarson@OncoThor·
I do not often post about papers on smoldering multiple myeloma but when I do, I make sure they are written by my favorite dysproteinemia experts... 😃 I actually came to Mayo as a fellow interested in myeloma (who wouldn't...?) over 20 years ago but then I somehow went off the rails but the fascination with dysproteinemic disorders still remains... This is a good review! @ZanwarSaurabh @VincentRK @myelomaMD nature.com/articles/s4157…
English
1
10
47
5.4K
john Given retweeté
Sean
Sean@S_Gallagher23·
FDA just rewrote the CAR-T approval rulebook. Randomized trials. Superiority over SOC. No more single-arm shortcuts. Every program built on the old model is now repricing risk. Here's what changed - and what it means for sponsors and investors: jamanetwork.com/journals/jama/…
English
15
45
178
36.9K
john Given retweeté
UK Defence in Dublin
UK Defence in Dublin@UKDefenceDublin·
Huge congratulations to Brigadier General Mark Brownen on his appointed and promotion as the new Irish 🇮🇪 @defenceforces General Officer Commanding the Defence Forces Training Centre….⬇️
Óglaigh na hÉireann@defenceforces

Brigadier General Mark Brownen has been appointed as General Officer Commanding the Defence Forces Training Centre by the Minister of Defence and Government. A native of County Cork, Brigadier General Brownen is a professional Infantry officer with over 40 years’ experience in a variety of roles across the Defence Forces as well as deployments with the United Nations, NATO and EU. Brigadier General Brownen has served in a wide variety of appointments throughout his career in both operations and command. He has served as the Director of Infantry of the Defence Forces and as Staff Officer and Instructor in a variety of Defence Forces Headquarters and Military College appointments. He has had several command appointments including the 3rd Infantry Battalion, 1 Mechanised Infantry Battalion and as Officer Commanding the 57 Infantry Group UNDOF, in Syria. His overseas experience includes multiple deployments to Lebanon, Chad, Afghanistan, Cote de Ivoire, Mali, Syria, and Kosovo. Brigadier General Brownen has been an active participant and leader of the Defence Forces Diving Group and Defence Forces Adventure Group throughout his career and is currently the President of both groups. Brigadier General Brownens’ educational qualifications include a Bachelor of Arts from NUIG, an MA in Leadership, Management & Defence Studies from MU and a Diploma in French from the University of Westminster. He is a graduate of the Defence Forces’ Command & Staff Course.

English
2
3
47
3.2K
john Given retweeté
michaeltmccarthy
michaeltmccarthy@mccarthymt7·
Often in cases of advanced cancer, when nothing more can be done, people prefer to go home. I understand why. A limiting factor here is nursing care at home. The @IrishCancerSoc bridges this gap, free of charge. Final wishes, delivered with care. I do not think it is possible to grade a service like this, but if it was possible, it would be A+. First class honours, 5 stars. Ten out of ten. Pure kindness in motion, in plain sight.
Arlene Harris@ArleneHarris11

In @IrishTimes I spoke to an @IrishCancerSoc night nurse and a woman whose family availed of their services. She urges people to support the charity on #DaffodilDay and help them to continue to provide support for cancer patients & their families. irishtimes.com/health/your-we…

English
0
14
88
4.2K
john Given retweeté
Yan Leyfman, MD
Yan Leyfman, MD@YLeyfman·
In vivo CAR-T generation—no manufacturing required? Engineered T cells have transformed oncology—but ex vivo manufacturing remains a major bottleneck (time, cost, access). A new study takes a major step toward making CAR-T directly inside the patient 👇 🔧 The innovation: • Two-vector system delivering CRISPR–Cas9 + DNA template • Site-specific integration of CAR into a T cell–specific locus • Combines precision editing + targeted delivery 🧪 What they achieved: • Stable, durable CAR expression in vivo • Therapeutic levels of CAR-T cells generated without ex vivo expansion • Efficacy across B-cell aplasia, hematologic + solid tumor models ⚠️ Why this matters: Current in vivo approaches → ❌ transient expression OR ❌ random integration This approach → ✅ precise ✅ durable ✅ cell-specific 💡 Big picture: A potential path to scalable, off-the-shelf CAR-T therapies—dramatically expanding access beyond specialized centers. 🧠 Takeaway: If validated in humans, this could redefine how we deliver cellular immunotherapy—from bespoke manufacturing → programmable in vivo engineering. nature.com/articles/s4158… #CARTcells #GeneEditing #CRISPR #Immunotherapy #CellTherapy #TranslationalScience #Oncology
English
5
13
32
1.8K
john Given retweeté
Yan Leyfman, MD
Yan Leyfman, MD@YLeyfman·
Frontline CAR-T for newly diagnosed multiple myeloma? A phase II trial explored BCMA CAR-T therapy as frontline treatment for patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for or not proceeding to transplant. 🧪 Study design: • Induction (3–4 cycles) → BCMA CAR-T infusion → consolidation + lenalidomide maintenance • 36 patients infused • Median age: 68 years 📊 Striking results: • MRD negativity: 100% at 3 months (10⁻⁵ sensitivity) • No MRD recurrence at median follow-up of 15.8 months • CR rate improved from 33% pre-infusion → 69% at 3 months → 94% at last follow-up ⚠️ Safety profile: • Cytopenias common but transient • Cytokine release syndrome: 52.8% (all grade 1–2) • Neurotoxicity: 5.6% (all grade 1) • No deaths or disease progression at data cutoff 💡 Why it matters: Patients who cannot undergo transplant often have fewer therapeutic opportunities. Early CAR-T may offer deep, durable remissions in the frontline setting. 🚀 Takeaway: Frontline BCMA CAR-T could represent a practice-changing strategy for transplant-ineligible NDMM—pending larger confirmatory trials. ascopubs.org/doi/10.1200/JC… #MultipleMyeloma #CARTcells #BCMA #Hematology #CancerImmunotherapy #ClinicalTrials #MRD
English
0
14
45
4.5K
john Given retweeté
Harold J. Burstein, MD, PhD, FASCO
Harold J. Burstein, MD, PhD, FASCO@DrHBurstein·
Shocking disparities in utilization of essential cancer meds across the US. Or maybe not so shocking anymore . By the way, if you want great care, start in Massachusetts @DanaFarber
Sasha Gusev@SashaGusevPosts

Since people are talking about cutting-edge cancer treatments, it is good to remember that in many states patients do not receive targeted therapies that they are approved for. There's a lot of alpha in getting healthcare in the US to look like it does in MA, HI, and NY.

English
5
18
58
11.3K
john Given retweeté
RoyK
RoyK@roy_kinsella·
Cadet pay is not just low; it is shockingly low. In real terms, cadets are paid far below the national minimum wage for the hours they work. More striking still, they are paid significantly less than an enlisted recruit. jrnl.ie/6980212
English
2
3
35
3.5K
john Given retweeté
Tedros Adhanom Ghebreyesus
Tedros Adhanom Ghebreyesus@DrTedros·
Global military expenditure just hit $2.7 trillion - in a single year. According to @UN estimates, ending world hunger by 2030 would require $93 billion annually. That means we spend almost 30 times more every year on killing each other than on making sure everyone eats. Numbers don't lie. Our priorities do.
Tedros Adhanom Ghebreyesus tweet media
English
192
2K
3.2K
151.2K
john Given retweeté
Dr Rishabh Jain
Dr Rishabh Jain@DrRishabhOnco·
Not all chemo toxicity needs dose reduction. A new phase III NEJM trial shows romiplostim can prevent chemotherapy dose delays caused by thrombocytopenia. For years, chemotherapy-induced thrombocytopenia (CIT) has forced oncologists to reduce or delay treatment. This study tests whether a TPO receptor agonist can maintain dose intensity. 🧪 Trial design Phase III, double-blind RCT Patients: GI cancers on oxaliplatin-based chemotherapy with persistent CIT Randomization: Romiplostim vs placebo (2:1) N = 165 📊 Primary endpoint No CIT-related chemo dose modification in cycles 2–3 📈 Results • No chemo dose modification: 84% vs 36% • Odds ratio: 10.16 • Platelet response: 97% vs 77% • Median platelet recovery: 1.1 vs 2.1 weeks ⚠️ Safety Grade ≥3 adverse events: 37% vs 22% 🎯 Takeaway Romiplostim significantly reduces chemotherapy delays and dose reductions from thrombocytopenia, potentially preserving dose intensity in GI cancer chemotherapy. If confirmed in broader populations, this could become the first effective strategy for CIT management. 🔖 Save this for clinic. 📖 Full paper in comment ⬇️ #OncoTwitter #MedTwitter #GIcancer #Thrombocytopenia @OncoAlert @ASCO @myESMO @NEJM
Dr Rishabh Jain tweet media
English
2
29
80
5.5K
john Given retweeté
Keith Siau
Keith Siau@drkeithsiau·
🚨 New head-to-head RCT in @NEJM: apixaban vs rivaroxaban 🥊 🏆 Apixaban emerges as the safe winner, with half the risk of bleeding complications 💡 For patients at high risk of GI bleeding, apixaban may be preferrable to rivaroxaban nejm.org/doi/full/10.10…
Keith Siau tweet media
English
16
281
984
358.5K
john Given retweeté
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP@RahulBanerjeeMD·
Brilliantly written by @Rfonsi1 about CARTITUDE-4 MajesTEC-3 in myeloma #MMsm. With cross-trial ⚠️, tec-dara 3-yr PFS 83% hard to beat. But as noted below, early PFS dropoff with cilta-cel from pre-infusion PD… not as big of issue in non-CART4 setting. Plus time off Tx!
Rahul Banerjee, MD, FACP tweet media
Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽@Rfonsi1

My thoughts on the selection of the best therapy for a myeloma patient experiencing a first relapse: cilta-cel versus teclistamab plus daratumumab? #mmsm open.substack.com/pub/rafaelfons…

English
4
5
30
9.2K

Découvrir

@ColoradoBlood @ZanwarSaurabh @VincentRK @myelomaMD @defenceforces @IrishCancerSoc @JCO_ASCO @ASCO